Skip To Main Content
Euronext Growth on Muck Rack

Euronext Growth

As seen in: This is Money, MarketScreener, FinanzNachrichten.de, MFN.se, Investing, Markets & Money, Sparda-Bank web.Börsenforum
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Euronext

Contact Euronext, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

EXACT Therapeutics - webcast presentation

|
By Euronext Growth, Anders Wold, Per Walday
| MFN.se
Oslo, Norway, 4 June 2026. Reference is made to the stock exchange announcement published 1 June 2026 by EXACT Therapeutics AS (the "Company", Euronext Growth ticker: EXTX), a clinical-stage precision medicine company, announcing that Company will host a webcast in connection with the proposed delisting of the Company's ordinary shares from Euronext Growth, Oslo on Thursday, 4 June 9.30 CEST.
Open in Who Shared View Duplicates (2) Issue with article?

EXACT Therapeutics: Announces webcast regarding strategic intent to delist the company's shares from listing on Euronext Growth, Oslo

|
By Euronext Growth, Anders Wold, Per Walday
| MFN.se
Oslo, Norway, 1 June 2026. Reference is made to the stock exchange announcement published 29 May 2026 by EXACT Therapeutics AS (the "Company", Euronext Growth ticker: EXTX), a clinical-stage precision medicine company, announcing that the Board proposes a delisting of the Company's ordinary shares, which are currently listed on Euronext Growth Oslo.
Open in Who Shared View Duplicates (2) Issue with article?

EXACT Therapeutics - First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer

|
By Euronext Growth, Harpreet Wasan
| MFN.se
Oslo, Norway, 3 March 2026. EXACT Therapeutics (the "Company", Euronext Growth ticker: EXTX), a clinical-stage precision medicine company, today announced that the first patient has been dosed in Europe in its Phase 2 ENACT trial. The recruitment takes place at three hospital sites in Europe, in addition to seven sites in the U.S. All sites are now active.
Open in Who Shared View Duplicates (6) Issue with article?
See all 28 licensed articles (29 Total)